With the launch of the first integration between SUI and Securitize, the tokenized fund HINC has entered the SUI ecosystem. SUI announced on its official X account that the first integration with Securitize has begun, stating that HINC will bring high-yield bonds, collateralized loan obligations (CLOs), and leveraged loans on-chain. This integration differs from the previous trend where existing tokenized funds primarily focused on U.S. Treasury bonds and money market funds (MMFs). The high-yield bonds included in HINC are issued by companies with relatively high credit risk, while CLOs are structured products created by bundling various loan receivables. Leveraged loans are debt-type loans used for mergers and acquisitions or corporate financial activities. Securitize has been expanding its institutional products in the field of real-world asset (RWA) tokenization. In an announcement in October 2025, Securitize revealed the launch of a tokenized fund STAC targeting AAA-rated CLOs in collaboration with BNY. SUI is also prominently showcasing use cases in institutional finance and capital markets. On its institutional and capital market introduction page, SUI explains that it can bring high-quality assets such as Treasury bonds and MMFs on-chain as collateral and automate the issuance, interest payment, and settlement processes through smart contracts. The specific conditions regarding HINC's management scale, investor requirements, issuance structure, and custodians have not been disclosed.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.